Recipharm has acquired Lisbon-based CDMO Lusomedicameta Sociedade Técnica Farmacêutica S.A. in a transaction valued at €112.3 million. An additional €1.3 million will be paid in 2015 subject to Lusomedicamenta’s 2014 financial performance. The acquisition expands Recipharm’s scale and profitability with combined revenue of SEK 2.7 billion based on LTM September 2014.   Lusomedicamenta brings significant export activities, expanding Recipharm’s access to new markets and customers. The existing ma...